Prolonged SARS-CoV-2 Viral Shedding in Patients with COVID-19 was Associated with Delayed Initiation of Arbidol Treatment and Consulting Doctor Later: A Retrospective Cohort Study

Abstract

Objective

To study data about SARS-CoV-2 virus shedding and clarify the risk factors for prolonged virus shedding.

Methods

Data were retrospectively collected from adults hospitalized with laboratory-confirmed coronavirus disease-19 (COVID-19) in Wuhan Union Hospital. We compared clinical features among patients with prolonged (a positive SARS-CoV-2 RNA on day 23 after illness onset) and short virus shedding and evaluated risk factors associated with prolonged virus shedding by multivariate regression analysis.

Results

Among 238 patients, the median age was 55.5 years, 57.1% were female, 92.9% (221/238) were administered with arbidol, 58.4% (139/238) were given arbidol in combination with interferon. The median duration of SARS-CoV-2 virus shedding was 23 days (IQR, 17.8–30 days) with a longest one of 51 days. The patients with prolonged virus shedding had higher value of D-dimer (P=0.002), IL-6 (P<0.001), CRP (P=0.005) and more lobes lung lesion (P=0.014) on admission, as well as older age (P=0.017) and more patients with hypertension (P=0.044) than in those the virus shedding less than 23 days. Multivariate regression analysis revealed that prolonged viral shedding was significantly associated with initiation arbidol >8 days after symptom onset [OR: 2.447, 95% CI (1.351–4.431)], ≥3 days from onset of symptoms to first medical visitation [OR: 1.880, 95% CI (1.035–3.416)], illness onset before Jan. 31, 2020 [OR: 3.289, 95% CI (1.474–7.337)]. Arbidol in combination with interferon was also significantly associated with shorter virus shedding [OR: 0.363, 95% CI (0.191–0.690)].

Conclusion

Duration of SARS-CoV-2 virus shedding was long. Early initiation of arbidol and arbidol in combination with interferon as well as consulting doctor timely after illness onset were helpful for SARS-CoV-2 clearance.

Keywords

SARS-CoV-2 / viral shedding / risk factors / antiviral treatment / arbidol

References

[1] Johns Hopkins University. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE). Available at: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. Accessed 8 September 2020.

[2] World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020. Available at: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. Accessed 8 September 2020.

[3] JinY, YangH, JiW, et al.. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses, 2020, 12(4): 372

[4] XuZ, ShiL, WangY, et al.. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020, 8(4): 420-422

[5] FieldingJE, KellyHA, MercerGN, et al.. Systematic review of influenza A(H1N1) pdm09 virus shedding: duration is affected by severity, but not age. Influenza Other Respir Viruses, 2014, 8(2): 142-150

[6] WangY, GuoQ, YanZ, et al.. Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection. J Infect Dis, 2018, 217(11): 1708-1717

[7] RyooSM, KimWY, SohnCH, et al.. Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days. Influenza Other Respir Viruses, 2013, 7(5): 833-837

[8] LeeN, ChanPK, HuiDS, et al.. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis, 2009, 200(4): 492-500

[9] KanchanaS, KanchanaS, ChuntrakulC, et al.. Pandemic (H1N1) 2009 virus infection: persistent viral shedding after Oseltamivir treatment. J Infect, 2011, 63(4): 295-299

[10] National Health Commission of the People’s Republic of China. Diagnosis and Treatment Program of New Coronary Pneumonia (the eighth edition). 2020. Available at: http://www.nhc.gov.cn/xcs/zhengcwj/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml. Accessed 8 September 2020.

[11] Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment. U.S. Food and Drug Administration; 2020. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. Accessed 1 May2020.

[12] Liu Q, Fang X, Tian L, et al. The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real world date from three hospitals in Wuhan. medRxiv 2020.

[13] BeigelJH, TomashekKM, DoddLE, et al.. Remdesivir for the Treatment of Covid-19 — Preliminary Report. N Engl J Med, 2020, 383(10): 994

[14] Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020.

[15] ChenJ, LiuD, LiuL, et al.. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban (Chinese), 2020, 49(2): 215-219

[16] Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. MedRxiv. 2020.

[17] RECOVERY Collaborative GroupHorby^PLim^WS. Dexamethasone in Hospitalized Patients with Covid-19—Preliminary Report. N Engl J Med, 2021, 384(8): 693-704

[18] World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. January 28, 2020. Available at: https://www.who.int/publications-detail/clinical-management-of-severeacute-respiatory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected. Accessed 8 September 2020.

[19] HuangC, WangY, LiX, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395: 497-506

[20] ZhouF, YuT, DuR, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, 395(10229): 1054-1062

[21] de JongMD, SimmonsCP, ThanhTT, et al.. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med, 2006, 12(10): 1203-1207

[22] GuJ, XieZ, GaoZ, et al.. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet, 2007, 370(9593): 1137-1145

[23] WuC, ChenX, CaiY, et al.. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med, 2020, 180(7): 934-943

[24] TreanorJJ, HaydenFG, VroomanPS, et al.. Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial. JAMA, 2000, 283(8): 1016-1024

[25] AokiFY, BoivinG. Influenza virus shedding: excretion patterns and effects of antiviral treatment. J Clin Virol, 2009, 44(4): 255-61

[26] NicholsonKG, AokiFY, OsterhausA, et al.. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet, 2000, 355(9218): 1845-1850

[27] HuF, YinG, ChenY, et al.. Corticosteroid, oseltamivir and delayed admission are independent risk factors for prolonged viral shedding in patients with Coronavirus Disease 2019. Clin Respir J, 2020, 14(11): 1067-1075

[28] HulsebergCE, FeneantL, Szymanska-de WijsKM, et al.. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses. J Virol, 2019, 93(8): e02185-18

[29] BlaisingJ, PolyakSJ, PecheurEI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res, 2014, 107: 84-94

[30] KhamitovRA, LoginovaS, ShchukinaVN, et al.. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol, 2008, 53(4): 9-13

[31] WangZ, YangB, LiQ, et al.. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis, 2020, 71(15): 769-777

[32] StockmanLJ, BellamyR, GarnerP. SARS: systematic review of treatment effects. PLoS Med, 2006, 3(9): e343

[33] YinY, WunderinkRG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology, 2018, 23(2): 130-137

[34] ChenRC, TangXP, TanSY, et al.. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest, 2006, 129(6): 1441-1452

[35] ArabiYM, MandourahY, Al-HameedF, et al.. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med, 2018, 197(6): 757-767

[36] HuZ, LvY, XuC, et al.. Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression. Front Public Health, 2020, 8: 355

[37] GarretsonTA, ShangH, SchulzAK, et al.. Expression-and genomic-level changes during passage of four baculoviruses derived from bacmids in permissive insect cell lines. Virus Res, 2018, 256: 117-1124